Rosiglitazone is a type 2 diabetes drug in the thiazolidinedione class. In 2011, the U.S. Food and Drug Administration determined that rosiglitzone posed a substantial risk for causing premature cardiovascular disease such as heart attacks. The agency greatly restricted prescribers, essentially killing the drug’s sales in the U.S. In November, the FDA took another look at the data and decided the risk was minimal or non-existent.
Dr. Steven Nissen of the Cleveland Clinic is on record as opposing the new change.
A lot of personal injury lawyers will be disappointed in the change unless they’ve already settled their cases out of court.
One response to “FDA Reversal: Rosiglitazone DOES NOT Pose Cardiovascular Risk”
From where I sit; I had to get off actos as my body was swelling with excess fluid and kidneys were going down hill. How cum that is not mentioned.
My kidney Doctor got me off that drug and my kidneys stabilized and stop going down hill. How is it FDA has not dealt or mentioned this issue.